Innovotech Inc. Reports Record Third Quarter Revenue Driven by Antimicrobial Research and Laboratory Services Growth
Innovotech Inc. achieved record Q3-2025 revenue of $1.27 million, demonstrating strong performance across its antimicrobial research services and analytical laboratory divisions while positioning for continued expansion.
Innovotech Inc. (TSX-V: IOT) reported record quarterly revenues of $1,267,692 for the third quarter of 2025, marking a significant milestone for the diversified Canadian technology company. The strong financial performance included net income of $92,945 and brings year-to-date revenues to $3,410,204, reflecting the company's strategic growth initiatives across its specialized service portfolio.
CEO Craig Milne attributed the positive results to multiple parallel efforts and investments supporting the company's expansion. "The Company has been building a foundation for continued growth and making multiple parallel efforts and investments to support expansion," Milne stated. "We are pleased to see the financial performance reflecting the changes underway."
The revenue growth stems from several key factors, including increasing demand for antimicrobial contract research services and strong performance from analytical services provided through Keystone Labs Inc., the company's wholly-owned subsidiary. Keystone Labs operates as a DEL-accredited laboratory serving the Canadian pharmaceutical industry and industrial markets, with additional information available at https://www.keystonelabs.ca.
Innovotech's diversified business model includes specialized laboratory services, biotechnology operations, and proprietary intellectual property. The company's contract research organization, Innovotech Labs Corporation, provides proprietary devices for antimicrobial testing across multiple applications and commercializes antimicrobial silver solutions. More details about these services can be found at https://www.innovotech.ca.
The company's strategic positioning extends beyond its core services through its 60% stake in NouLifeSciences Inc., which holds intellectual property related to antioxidant molecules with potential applications in cosmetics and various medical conditions including neuropathies. This diversified approach provides multiple revenue streams while leveraging the company's technical expertise in specialized laboratory services.
The record quarterly performance demonstrates Innovotech's ability to capitalize on growing market demand for specialized testing and research services, particularly in the antimicrobial and pharmaceutical sectors. The company's expansion efforts appear to be yielding tangible financial results, positioning it for sustained growth in competitive technology and laboratory service markets.